Merck known as MSD outside of the United States and Canada, announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the ...
Turn Biotechnologies, a pioneer in epigenetic reprogramming, announced the acquisition of the company's groundbreaking ARMMs (ARRDC1-mediated microvesicles...
Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced pharmacokinetic a...
Soleno Therapeutics, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced that the U.S. Food and D...
The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary pr...
B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced the launch of its new Cefazolin 3 g, the latest cefazol...
Actinium Pharmaceuticals, Inc.(Actinium or the Company), a pioneer in the development of targeted radiotherapies, announced it has entered into an agreemen...
Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned s...
Paratek Pharmaceuticals and Optinose, Inc. announced they have entered into a definitive merger agreement under which Paratek will acquire Optinose, includ...
Cumberland Pharmaceuticals Inc. a specialty pharmaceutical company with development efforts focused on rare diseases, announced that results from its Phase...
Moon Surgical, a French-American pioneer in surgical innovation, announced the United States Food and Drug Administration (FDA) clearance for ScoPilot. Ena...
Signal12, Inc., a clinical-stage ophthalmic pharmaceutical company focused on first-of-a-kind patented technologies that enable existing drugs to act...
Whitehawk Therapeutics, Inc. formerly known as Aadi Bioscience, Inc., an oncology therapeutics company applying advanced technologies to establis...
Mozart Therapeutics, the leading developer of CD8 Treg modulators for the treatment of autoimmune disease, announce the successful completion of thei...
© 2025 Biopharma Boardroom. All Rights Reserved.
